Joint ESGO-ESTRO-ESP: Endometrial cancer guidelines update
Nicole Concin,
Austria;
,
The Netherlands;
Sigurd Lax,
Austria
Over the last 5 years there have been many practice changing developments in the management of endometrial carcinoma. The role of molecular markers, their impact on risk estimation and treatment decisions has evolved. Therefore, the FIGO staging system has been revised in 2023 to include molecular markers. In 2025, the ESGO-ESTRO-ESP guidelines on the management of endometrial carcinoma have been updated according to the latest evidence.
Symposium
Clinical
Gynaecology